Recent studies have shown that low-molecular-weight heparins (LMWH) ar
e not suitable for treating patients with heparin-associated thrombope
nia (HAT) type 2, as they can cause the same complications as unfracti
onated heparin UFH. The case described ist that of concerns as female
patient who died after developing HAT type 2 following LMWH given peri
operatively to prevent thromboembolism. This case indicates again that
LMWH can trigger HAT type 2 even if administered only once a day. For
HAT to be successfully treated it is essential that the condition is
diagnosed early enough by means of routine regular laboratory checks o
f the number of thrombocytes during any heparin treatment in order to
detect the disease before clinical symptoms become apparent.